South San Francisco, United States
Graphite Bio, founded in 2020 and headquartered in the United States, is a clinical-stage biotechnology company revolutionizing the field of gene editing. The company aims to eliminate the term "incurable," as captured by their slogan, "Creating a future where the word 'incurable' no longer exists."
Graphite Bio is pioneering a groundbreaking approach to precision gene editing with its proprietary UltraHDR™ platform. This technology leverages the power of high-efficiency precision DNA repair to go beyond conventional CRISPR capabilities, offering a potential leap forward in treating serious and life-threatening diseases. Co-founded by esteemed scientists Maria Grazia Roncarolo, M.D., and Matthew Porteus, M.D., Ph.D., the company is set on transforming healthcare outcomes by effectively correcting genetic mutations and offering novel cures.
In its most recent funding event, Graphite Bio received an acquisition investment on 01 March 2024 from Merz Therapeutics. This strategic infusion is expected to bolster the company's efforts to expand its curative therapies to a broader patient base.
